Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

135
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
135
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

83
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
83
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

532
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
532
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

328
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adult separation anxiety and feelings of guilt as predictors of prolonged grief disorder.

International journal of psychiatry in clinical practice·2025
Same author

Evaluation of the Role of Affective Temperamental Features, Automatic Thoughts, and Symptom Interpretation on Disease Activity in Patients with Axial Spondyloarthritis.

Alpha psychiatry·2023
Same author

Heterogeneity of associations between dissociation and attention deficit symptoms.

Current psychology (New Brunswick, N.J.)·2022
Same author

Investigation of the correlation between mood disorder symptoms and disease activity and functional status in rheumatoid arthritis patients

Turkish journal of medical sciences·2021
Same author

Dissociative Experiences Associated With Internet Gaming Disorder After Controlling For Childhood Trauma And ADHD Diagnosis.

Journal of trauma & dissociation : the official journal of the International Society for the Study of Dissociation (ISSD)·2021

Related Experiment Video

Updated: Jun 6, 2025

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

79.7K

Decrease in Serum Lithium Levels Induced by Ursodeoxycholic Acid: A Case Report.

Gizem Gulpamuk1, Kursat Altinbas1

  • 1Department of Psychiatry, Selcuk University, Konya, Turkey.

Psychiatry and Clinical Psychopharmacology
|December 2, 2024
PubMed
Summary

Lithium is crucial for bipolar disorder but drug interactions can alter levels. Ursodeoxycholic acid unexpectedly decreased lithium levels in a patient, highlighting potential risks.

Keywords:
Bipolar disorderlithiumursodeoxycholic acid

More Related Videos

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

231
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.1K

Related Experiment Videos

Last Updated: Jun 6, 2025

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

79.7K
Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

231
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.1K

Area of Science:

  • Pharmacology
  • Psychiatry
  • Hepatology

Background:

  • Lithium is a primary treatment for bipolar disorder, requiring careful serum level monitoring due to its narrow therapeutic index.
  • Drug interactions can significantly impact lithium levels, potentially leading to toxicity or relapse of mood episodes.
  • Awareness of potential interactions with medications from various specialties is crucial for safe lithium therapy.

Purpose of the Study:

  • To report a case of significantly decreased lithium levels after the introduction of ursodeoxycholic acid.
  • To explore the potential interaction mechanism between lithium and ursodeoxycholic acid.

Main Methods:

  • Case report presentation.
  • Review of current literature on drug interactions with lithium and ursodeoxycholic acid.

Main Results:

  • A patient on long-term lithium therapy with stable serum levels experienced a rapid decrease in lithium levels after initiating ursodeoxycholic acid.
  • Literature review suggested potential mechanisms for this interaction.

Conclusions:

  • Ursodeoxycholic acid may decrease serum lithium levels.
  • Clinicians should consider this potential interaction when co-prescribing lithium and ursodeoxycholic acid.
  • Further research is warranted to elucidate the interaction mechanism and clinical implications.